Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aurelio Cafaro

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Expert Review of Vaccines|June 13, 2022
HIV-1 therapeutic vaccines in clinical development to intensify or replace antiretroviral therapy: the promising results of the Tat vaccineAurelio Cafaro, Barbara Ensoli
Current Opinion in Biotechnology|November 25, 2004
Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccinesFlavia Ferrantelli, Aurelio Cafaro, Barbara Ensoli
Springer Seminars in Immunopathology|September 20, 2006
Building collaborative networks for HIV/AIDS vaccine development: the AVIP experienceFlavia Ferrantelli, Stefano Buttò, Aurelio Cafaro, et al.
Frontiers in Immunology|September 25, 2014
Challenges in HIV Vaccine Research for Treatment and PreventionBarbara Ensoli, Aurelio Cafaro, Paolo Monini, et al.
Advances in Experimental Medicine and Biology|January 5, 2010
Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDSAurelio Cafaro, Iole Macchia, Maria Teresa Maggiorella, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2001
Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responsesEmanuele Fanales-Belasio, Sonia Moretti, Filomena Nappi, et al.
Vaccines|August 29, 2019
Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the DiseaseAurelio Cafaro, Antonella Tripiciano, Orietta Picconi, et al.
Expert Review of Vaccines|January 21, 2020
HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapySonia Moretti, Aurelio Cafaro, Antonella Tripiciano, et al.
BMC Infectious Diseases|August 24, 2016
HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathologyAurelio Cafaro, Giovanni Piccaro, Giuseppe Altavilla, et al.
Vaccines|June 10, 2020
The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral ReactivationFrancesco Nicoli, Eleonora Gallerani, Mariaconcetta Sicurella, et al.
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Expert Review of Vaccines|June 13, 2022
HIV-1 therapeutic vaccines in clinical development to intensify or replace antiretroviral therapy: the promising results of the Tat vaccineAurelio Cafaro, Barbara Ensoli
Current Opinion in Biotechnology|November 25, 2004
Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccinesFlavia Ferrantelli, Aurelio Cafaro, Barbara Ensoli
Springer Seminars in Immunopathology|September 20, 2006
Building collaborative networks for HIV/AIDS vaccine development: the AVIP experienceFlavia Ferrantelli, Stefano Buttò, Aurelio Cafaro, et al.
Frontiers in Immunology|September 25, 2014
Challenges in HIV Vaccine Research for Treatment and PreventionBarbara Ensoli, Aurelio Cafaro, Paolo Monini, et al.
Advances in Experimental Medicine and Biology|January 5, 2010
Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDSAurelio Cafaro, Iole Macchia, Maria Teresa Maggiorella, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2001
Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responsesEmanuele Fanales-Belasio, Sonia Moretti, Filomena Nappi, et al.
Vaccines|August 29, 2019
Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the DiseaseAurelio Cafaro, Antonella Tripiciano, Orietta Picconi, et al.
Expert Review of Vaccines|January 21, 2020
HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapySonia Moretti, Aurelio Cafaro, Antonella Tripiciano, et al.
BMC Infectious Diseases|August 24, 2016
HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathologyAurelio Cafaro, Giovanni Piccaro, Giuseppe Altavilla, et al.
Vaccines|June 10, 2020
The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral ReactivationFrancesco Nicoli, Eleonora Gallerani, Mariaconcetta Sicurella, et al.
Pageof 7